ArticleBiochemistry2009
Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins.
Article in Biochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 18 citations in OpenAlex.
- Trial
- Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.Arteriosclerosis, thrombosis, and vascular biology · 2013Trial
- Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.Journal of thrombosis and haemostasis : JTH · 2018Article
- Structural Stability of Streptococcal Serum Opacity Factor.The protein journal · 2017Article
- Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism.Biochemistry · 2015Article
- Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.The Journal of biological chemistry · 2014Article
- Functional and structural properties of a novel protein and virulence factor (Protein sHIP) in Streptococcus pyogenes.The Journal of biological chemistry · 2014Article
- Influence of apolipoprotein A-I and apolipoprotein A-II availability on nascent HDL heterogeneity.Journal of lipid research · 2013Article
- Comparison of apoA-I helical structure and stability in discoidal and spherical HDL particles by HX and mass spectrometry.Journal of lipid research · 2013Article
- Interactions of apolipoprotein A-I with high-density lipoprotein particles.Biochemistry · 2013Article
- Apolipoprotein A-II-mediated conformational changes of apolipoprotein A-I in discoidal high density lipoproteins.The Journal of biological chemistry · 2012Article
- Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo.Arteriosclerosis, thrombosis, and vascular biology · 2011Article
- Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma.Nature structural & molecular biology · 2011Article
- Speciated human high-density lipoprotein protein proximity profiles.Biochemistry · 2010Article
- Tissue tropisms in group A streptococcal infections.Future microbiology · 2010Review
- The structure and function of serum opacity factor: a unique streptococcal virulence determinant that targets high-density lipoproteins.Journal of biomedicine & biotechnology · 2010Review
- Opacification Domain of Serum Opacity Factor Inhibits Beta-Hemolysis and Contributes to Virulence ofmSphereArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Human plasma HDL are the target of streptococcal serum opacity factor (SOF), a virulence factor that clouds human plasma. Recombinant (r) SOF transfers cholesteryl esters (CE) from approximately 400,000 HDL particles to a CE-rich microemulsion (CERM), forms a cholesterol-poor HDL-like particle (neo HDL), and releases lipid-free (LF) apo A-I. Whereas the rSOF reaction requires labile apo A-I, the modulation effects of other apos are not known. We compared the products and rates of the rSOF reaction against human HDL and HDL from mice overexpressing apos A-I and A-II. Kinetic studies showed that the reactivity of various HDL species is apo-specific. LpA-I reacts faster than LpA-I/A-II. Adding apos A-I and A-II inhibited the SOF reaction, an effect that was more profound for apo A-II. The rate of SOF-mediated CERM formation was slower against HDL from mice expressing human apos A-I and A-II than against WT mice HDL and slowest against HDL from apo A-II overexpressing mice. The lower reactivity of SOF against HDL containing human apos is due to the higher hydropathy of human apo A-I, particularly its C-terminus relative to mouse apo A-I, and the higher lipophilicity of human apo A-II. The SOF-catalyzed reaction is the first to target HDL rather than its transporters and receptors in a way that enhances reverse cholesterol transport (RCT). Thus, effects of apos on the SOF reaction are highly relevant. Our studies show that the "humanized" apo A-I-expressing mouse is a good animal model for studies of rSOF effects on RCT in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.